http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 04 Sep 2026 06:07:29 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Neutral+Rating+on+GlaxoSmithKline+%28GSK%3ALN%29+%28GSK%29/27027359.html <p>BofA Securities analyst Sachin Jain reiterated a Neutral rating and GBP23.50 price target on GlaxoSmithKline (GSK:LN) (NYSE: GSK).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Neutral+Rating+on+GlaxoSmithKline+%28GSK%3ALN%29+%28GSK%29/27027359.html Fri, 04 Sep 2026 06:07:29 -0400 GSK http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Neutral+Rating+on+GlaxoSmithKline+%28GSK%3ALN%29+%28GSK%29/27027359.html <p>BofA Securities analyst Sachin Jain reiterated a Neutral rating and GBP23.50 price target on GlaxoSmithKline (GSK:LN) (NYSE: GSK).</p> http://www.streetinsider.com/Intl+Ratings/BofA+Securities+Reiterates+Neutral+Rating+on+GlaxoSmithKline+%28GSK%3ALN%29+%28GSK%29/27027359.html Fri, 04 Sep 2026 06:07:29 -0400 GSK http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Sep+01/27011455.html si-local-file:///var/storage/secattach/20260901/27011455.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Sep+01/27011455.html Tue, 01 Sep 2026 12:26:00 -0400 GSK http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Sep+01/27008937.html si-local-file:///var/storage/secattach/20260901/27008937.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Sep+01/27008937.html Tue, 01 Sep 2026 07:46:00 -0400 GSK http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Aug+26/26978889.html si-local-file:///var/storage/secattach/20260826/26978889.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Aug+26/26978889.html Wed, 26 Aug 2026 10:38:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Aug+26/26978889.html si-local-file:///var/storage/secattach/20260826/26978889.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Aug+26/26978889.html Wed, 26 Aug 2026 10:38:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Aug+26/26978889.html si-local-file:///var/storage/secattach/20260826/26978889.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GSK+plc+++++++++++++++++++For%3A+Aug+26/26978889.html Wed, 26 Aug 2026 10:38:00 -0400 GSK GSK O.00496275 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221 http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html <p>The U.S. Food and Drug Administration has approved ViiV Healthcare's Tivicay PD (dolutegravir) for the treatment of HIV-1 infection in pediatric patients weighing at least 2 kg, including eligible newborns, according to a statement from the company.</p> <p>ViiV Healthcare, which is majority owned by GSK (LSE: GSK) with Shionogi as a shareholder, said the approval covers use in combination with other antiretroviral agents for treatment-naïve or treatment-experienced patients who are integrase strand transfer inhibitor (INSTI)-naïve. The company claims this makes Tivicay PD the first second-generation integrase inhibitor approved for children in this weight category.</p> <p>The FDA granted Priority Review for this indication. http://www.streetinsider.com/FDA/FDA+approves+ViiV+Healthcare%27s+Tivicay+PD+for+newborns+with+HIV/26978693.html Wed, 26 Aug 2026 10:14:15 -0400 A.04410117 A.06822034 A.19655944 A.25979495 A.29922014 A.38925042 A.40285882 A.50201316 A.50201952 GSK O.00496275 O.03285412 O.03307993 O.07030306 O.07332344 O.20026344 O.20046146 O.20118337 O.30953776 O.42081221